Overview
Hypoxia is the most common adverse event during gastrointestinal endoscopes sedated with propofol and sufentanil, especially in obese people. In the present study, high-flow nasal cannula oxygenation will be utilized in order to reduce the incidence of hypoxia among obesity.
Eligibility
Inclusion Criteria:
- patients undergoing gastrointestinal endoscopes
- age≥18 years old and ≤70 years old
- patients or family members signed informed consent form
- ASA classification I-II
- BMI≥ 28kg/m²
Exclusion Criteria:
- Coagulation disorders or a tendency of nose bleeding;
- An episode/exacerbation of congestive heart failure (CHF) that requires a change in medication, diet or hospitalization from any cause in the last 6 months;
- Severe aortic stenosis or mitral stenosis;
- Cardiac surgery involving thoracotomy (e.g., coronary artery bypass graft (CABG), valve replacement surgery) in the last 6 months;
- Acute myocardial infarction in the last 6 months;
- Acute arrhythmia (including any tachycardia - or bradycardia) with the fluid of hemodynamics instability;
- Diagnosed chronic obstructive pulmonary disease or current other acute or chronic lung disease requiring supplemental chronic or intermittent oxygen therapy);
- Increased intracranial pressure;
- ASA classification Ⅲ-Ⅳ ;
- Mouth, nose, or throat infection;
- Liver and kidney disease
- Fever, defined as core body temperature > 37.5℃;
- Pregnancy, breastfeeding or positive pregnancy test;
- Emergency procedure;
- Patients or family members refused to participate
- Mental disorders and people without civil capacity